

ACCESS TO SPECIALIZED CANCER CARE FOR PANCREATIC ADENOCARCINOMA

VISUAL RESEARCH ABSTRACT



OBJECTIVE

To determine the factors associated with access to medical oncology consultation and cancer-directed therapies in patients with pancreatic adenocarcinoma.

STUDY POPULATION

10 881 patients who were diagnosed with noncurative pancreatic adenocarcinoma in Ontario from 2005 to 2016.

SPECIALIZED CANCER CONSULTATION*



Despite potential for prolonging survival with cancer-directed therapy, many patients with advanced pancreatic cancer did not see a specialized cancer physician or receive such treatment.

Note: *First consultation after diagnosis; CI = confidence interval; RR = risk ratio.

Source: Mavros MN, Coburn NG, Davis LE, et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. *CMAJ* 2019;191:E574-80.

©2019 Joule Inc. or its licensors

cma
aj